Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.
about
Mammary gland stem cells and their application in breast cancerRCP is a human breast cancer-promoting gene with Ras-activating functionFerroportin and iron regulation in breast cancer progression and prognosisClustering gene expression data with a penalized graph-based metric.Comparative study of joint analysis of microarray gene expression data in survival prediction and risk assessment of breast cancer patients.Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data.The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis.Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancerA compact VEGF signature associated with distant metastases and poor outcomes.Can survival prediction be improved by merging gene expression data sets?Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.Expression signatures of TP53 mutations in serous ovarian cancers.Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft modelsNetwork pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients.Computational approach for deriving cancer progression roadmaps from static sample data.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesGene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile.A fuzzy gene expression-based computational approach improves breast cancer prognosticationClinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriersBasal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry.Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.Tracing the tumor lineage.How many etiological subtypes of breast cancer: two, three, four, or more?The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancersTargeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.Relation between radiographic BI-RADS scores and triple negativity in patients with ductal carcinomas.A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.Cancer progression modeling using static sample dataPrevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study.TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 productionNew advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrenceClinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma.Effects of age on the detection and management of breast cancer.Minireview: Basal-like breast cancer: from molecular profiles to targeted therapiesA simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.Household income is associated with the p53 mutation frequency in human breast tumorsEpidemiology of basal-like breast cancer.Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cellsWnt pathway activity in breast cancer sub-types and stem-like cellsThe changing role of pathology in breast cancer diagnosis and treatment.
P2860
Q28075791-5CE408B5-EFD3-43BF-A536-550654E427D3Q28252569-A7AC372A-6282-4A84-8546-61FA927DE827Q28289776-63EDDBB3-95BB-4AFA-A192-C12FC16C1567Q30993978-81DEAD1F-7606-4890-8B66-29396727488EQ31011613-9C7CC290-A180-4F70-AF5C-B338CEFEBB3DQ31142505-657416A7-3814-4141-9F28-C7D2FDABEBA7Q33370712-BEFD3B27-266A-42CE-B9EE-BCD06D08828BQ33396559-90B60BA8-A4C7-477A-A227-8977ABC36738Q33418745-D9B6151D-E8DB-4D92-8E34-4D09BD18D31DQ33511962-2AC4ECB0-D980-464E-A9F8-2A4E1D68FC65Q33573884-E45D297C-31DE-42AC-8480-06D8D1A02DFEQ33588196-52525BC4-3DD7-4335-8748-B1DA0642029BQ33660965-7EDF1461-093B-4494-A61C-677E258F734BQ33688907-431BBD1D-14DD-48EC-A603-7E5C0BB329B0Q33701691-D1811724-2243-489F-81AE-6308BEDA8B36Q33730375-748DAE01-AE0D-4F00-A25C-A622DD67F5E9Q33794872-713240D8-38B7-49D5-9F5E-4AC408C5ECC7Q33861620-8E7B92AF-4D65-416A-BD0B-81F39B706E30Q33863531-D37C46C6-6133-48E7-8758-B341F651A035Q33864102-D06D52CC-E8E7-4B58-8505-A9F42C18742BQ33875853-504956A4-2EBF-4CAD-9193-7C03FF35D454Q33998432-50686BB8-5727-4807-8EC6-E2B13F07E471Q34106175-779C7688-76D0-4FF1-92F7-AA6AC3AD2B5DQ34119756-5F00E7D9-306F-4789-829A-C73AEE935A86Q34162501-25F9B324-32CD-4811-8B1C-1773BBB074D0Q34167298-9798340F-64BD-4432-B774-0A30D4FB2BEBQ34268261-F90EE5FA-226F-445B-880B-FE0E5FCBFFBAQ34334159-977E63A9-7CEC-470E-B87E-6ADA191546E7Q34378272-208F5DA7-0600-47CF-BB68-65FA48305AEDQ34379330-6583FB10-0DBD-472C-ACCA-EB8693776D84Q34382914-8CBD931D-8C0A-4D89-8D73-9C03200660B9Q34474679-E935F97A-1834-4192-9EE9-AFFEE29BF692Q34477879-338A1298-F762-4A8E-9193-EE0D55A96131Q34562257-63759B2C-116D-4A50-9EC7-AB08D1CBB6E3Q34577709-F15679DD-F5C9-4BF5-8AC0-6D51375B81B4Q34613059-3F7B4A77-3E56-4936-8735-FEE54A449299Q34639174-C75CA45D-9B33-4F79-9263-B6353F6BCB5AQ34647893-B6D43B86-A78A-41AC-81CB-F59B79F784FFQ34826223-E0B07A8C-FB49-4114-8248-658787C66903Q35082260-CB06D79D-5DDB-40CC-88EF-B2E31956F29F
P2860
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Intrinsic molecular signature ...... -based cohort of 412 patients.
@ast
Intrinsic molecular signature ...... -based cohort of 412 patients.
@en
type
label
Intrinsic molecular signature ...... -based cohort of 412 patients.
@ast
Intrinsic molecular signature ...... -based cohort of 412 patients.
@en
prefLabel
Intrinsic molecular signature ...... -based cohort of 412 patients.
@ast
Intrinsic molecular signature ...... -based cohort of 412 patients.
@en
P2093
P2860
P50
P356
P1476
Intrinsic molecular signature ...... -based cohort of 412 patients.
@en
P2093
Edison T Liu
Johanna Smeds
Jonas Bergh
Judith Bjöhle
Sigrid Klaar
Ulrike Kronenwett
Yudi Pawitan
P2860
P2888
P356
10.1186/BCR1517
P577
2006-01-01T00:00:00Z
P5875
P6179
1004340956